Drugs / Autologous serum eyedrops
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01089985 | Jul 2010 → Dec 2011 | xerophthalmia | Singapore National Eye Centre | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06294015 | Mar 2024 → Dec 2025 | dry eye syndrome, glaucoma | University of Sherbrooke | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07469865 | Nov 2021 → Nov 2024 | dry eye syndrome | University Hospital, Ghent | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous serum eyedrops | “Participants receive 20% Autologous Serum Eye Drops prepared by the hospital laboratory from the patients blood, diluted with sterile 0.9% sodium chloride to achieve the...” NCT06294015 ↗ |
| Known as | ASED | “Autologous serum eye drops (ASED), contains essential growth factors and nutrients which may promote corneal and conjunctival integrity, offering benefits over traditional treatments.” NCT06294015 ↗ |
| Route | Other | “These drops are administered 6 times daily in one eye for two months.” NCT06294015 ↗ |